Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (57)	12/10/2002 5:55:52 PM
From: keokalani'nui	Read Replies (1) of 123

This is promising..... Merck To Update Analysts On Celltech Asthma Drug Tuesday December 10, 1:13 pm ET LONDON -(Dow Jones)- Merck & Co. will update analysts Tuesday on the progress of asthma drug PDE4, which it has licensed from U.K.-based Celltech PLC (NYSE:CLL - News; CLL), a Celltech spokesman said. Celltech shares firmed Tuesday on speculation that Merck would brief analysts about its plans for the drug, which is also in clinical trials for chronic obstructive pulmonary disorder. Celltech shares closed up 4% at 331.5 pence. Merck will say that Phase II clinical trials are ongoing for both asthma and COPD, Celltech spokesman Richard Bungay said. Merck will highlight its belief, based on data collected to date, that the drug is completely free of the emesis - or nausea - side effects seen with other similar drugs, Bungay added. ______________________ [Please also announce this is the one and only PDE4inh it will be pursuing....but do you get the feeling this has already been scripted?]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next